Serbia extended its tender for the Galenika AD drug company for a fourth time, giving a unit of Canada’s Valeant Pharmaceuticals International Inc until June 14 to file a bid, the Finance Ministry said on its website. The government first called for bidders on Jan. 15, seeking a partner among drugmakers with operating revenue of at least €200 million ($$259.5 million) in 2011. Galenika cut its 2012 loss to RSD 5.6 billion ($65.2 million) from RSD 13.5 billion a year earlier.